# Palliative Care Principles in Geriatrics
## Introduction
Palliative care is a specialized domain of medical practice focused on providing relief from the symptoms, pain, and stress associated with serious illness. It is appropriate at any stage of illness and is designed to be delivered concurrently with curative or disease-directed treatment. This distinguishes palliative care from hospice care, which represents a subset of palliative care specifically for patients with an estimated prognosis of six months or less who have elected to pursue comfort-focused care. Elderly patients bear a disproportionate burden of serious illness, including heart failure, chronic obstructive pulmonary disease, dementia, cancer, chronic kidney disease, and frailty, all of which generate substantial symptom burden and complex care needs.
Despite this high burden of need, only 15 to 30 percent of eligible elderly patients receive palliative care consultation. This gap between need and delivery represents a significant failure of the healthcare system. The landmark trial by Temel and colleagues in 2010, which randomized patients with metastatic non-small-cell lung cancer to early palliative care integrated with standard oncology care versus standard oncology care alone, demonstrated that early palliative care not only improved quality of life and reduced symptom burden but also conferred a 2.7-month median survival advantage. This trial fundamentally challenged the misconception that palliative care is relevant only at end of life and established that early integration of palliative care with disease-directed therapy can simultaneously improve quality and quantity of life.
## Core Principles
### Domains of Palliative Care (NCP Guidelines)
The National Consensus Project for Quality Palliative Care has defined eight domains that constitute the comprehensive scope of palliative care practice. The first domain encompasses structure and processes of care, ensuring that palliative care delivery is organized, coordinated, and interprofessional. The second domain addresses the physical aspects of care, centering on symptom management across the full range of distressing physical symptoms. The third domain covers psychological and psychiatric aspects, including depression, anxiety, delirium, and adjustment disorders. The fourth domain attends to social aspects, recognizing the impact of illness on family dynamics, social roles, and practical concerns such as finances and caregiving. The fifth domain addresses spiritual, religious, and existential aspects, which become increasingly salient as patients confront mortality and search for meaning. The sixth domain encompasses cultural aspects, ensuring that care is culturally sensitive and responsive to diverse traditions and values. The seventh domain focuses on care of the imminently dying patient, guiding the clinical management of the final hours and days. The eighth domain covers ethical and legal aspects, including informed consent, advance care planning, and the resolution of ethical dilemmas.
### Palliative Care vs. Hospice
| Feature | Palliative Care | Hospice |
|---------|----------------|---------|
| Timing | Any stage of serious illness | Prognosis ≤6 months |
| Concurrent curative treatment | Yes | Generally no (comfort-focused) |
| Prognosis requirement | None | ≤6 months certified by 2 physicians |
| Setting | Hospital, clinic, home | Home (most common), SNF, inpatient hospice |
| Coverage | Standard insurance/Medicare | Medicare Hospice Benefit |
| Services | Symptom management, goals-of-care | Nursing, HHA, DME, meds, chaplain, bereavement |
| Duration | Months to years | Median enrollment 18 days (ideally ≥3 months) |
The distinction between palliative care and hospice is a source of persistent confusion among patients, families, and clinicians, yet understanding this distinction is essential for appropriate referral and utilization. Palliative care is applicable at any stage of serious illness, can be delivered concurrently with disease-directed treatment, imposes no prognosis requirement, and can be provided in hospital, clinic, or home settings. Hospice, by contrast, is appropriate when the estimated prognosis is six months or less, the patient elects comfort-focused care and generally relinquishes most curative treatments, and care is provided under the Medicare Hospice Benefit, which covers medications, durable medical equipment, nursing services, home health aides, social work, chaplaincy, bereavement support, and respite care.
A critical problem in current practice is the timing of hospice enrollment. The median length of hospice enrollment in the United States is only 18 days, a duration that is far too short for patients and families to derive the full benefit of hospice services. Ideal hospice enrollment occurs at least three months before death, allowing sufficient time for comprehensive symptom management, psychological and spiritual support, caregiver education, and preparation for the dying process.
## Symptom Management in Geriatric Palliative Care
### Dyspnea
Dyspnea is consistently identified as the most distressing symptom experienced at end of life, with a prevalence of 50 to 70 percent in dying patients. Its management requires both non-pharmacological and pharmacological approaches. Non-pharmacological interventions include directing a fan toward the face, which reduces the sensation of dyspnea through trigeminal nerve stimulation, positioning the patient upright with support, maintaining a cool environment, providing supplemental oxygen when the patient is hypoxemic, and employing relaxation techniques. It is important to note that a fan directed at the face may be equally effective as supplemental oxygen in patients who are not hypoxemic.
Pharmacologically, opioids are the first-line treatment for dyspnea at end of life. Morphine at doses of 2 to 5 mg orally every 4 hours or 1 to 2 mg intravenously or subcutaneously every 2 to 4 hours reduces ventilatory drive and diminishes the subjective perception of breathlessness. Nebulized morphine, despite its intuitive appeal, has not been demonstrated to be more effective than systemic administration in Cochrane review analysis. Benzodiazepines serve as adjunctive therapy for dyspnea associated with anxiety; lorazepam at 0.5 to 1 mg sublingually or orally every 4 to 6 hours is a common choice. Dexamethasone at 4 to 8 mg daily is appropriate for specific etiologies including lymphangitic carcinomatosis, airway obstruction, and radiation pneumonitis. Supplemental oxygen should be provided only when the patient is hypoxemic, defined as an oxygen saturation below 88 percent; routine supplemental oxygen for non-hypoxemic dyspnea does not improve outcomes and adds unnecessary equipment burden.
### Nausea and Vomiting
Effective management of nausea and vomiting in palliative care requires identification of the underlying mechanism to guide treatment selection. When the chemoreceptor trigger zone is stimulated by drugs or metabolic derangements, haloperidol at 0.5 to 2 mg orally or intravenously every 6 hours or ondansetron at 4 to 8 mg are effective. Gastrointestinal causes such as gastroparesis respond to metoclopramide at 5 to 10 mg orally or intravenously three times daily, though this agent must be avoided in the setting of complete bowel obstruction. For malignant bowel obstruction, the combination of octreotide at 100 to 300 mcg subcutaneously three times daily, dexamethasone, and hyoscine butylbromide provides multimodal relief. Vestibular-mediated nausea is addressed with meclizine or a scopolamine transdermal patch. Raised intracranial pressure requires dexamethasone at 8 to 16 mg intravenously daily. Anticipatory nausea may respond to lorazepam at 0.5 to 1 mg or behavioral therapy. Olanzapine at 2.5 to 5 mg has emerged as a broad-spectrum antiemetic with growing evidence supporting its use across multiple nausea mechanisms.
### Fatigue
Fatigue is the most common symptom reported in serious illness, with a prevalence of 80 to 90 percent across disease types. The initial approach involves identifying and addressing reversible contributing factors, including anemia, hypothyroidism, depression, sedating medications, physical deconditioning, and sleep disturbance. Pharmacological management options include methylphenidate at 2.5 to 5 mg twice daily administered in the morning and at noon, avoiding administration after 2 PM to prevent insomnia. Dexamethasone at 2 to 4 mg provides short-term improvement in energy and appetite but is unsuitable for long-term use. Non-pharmacological approaches include energy conservation strategies, graded exercise programs adapted to the patient's capacity, sleep hygiene optimization, and occupational therapy consultation.
### Anorexia and Cachexia
The clinical approach to anorexia and cachexia begins with distinguishing treatable causes, such as medication side effects, oral pathology, and depression, from disease-related cachexia, which represents an irreversible metabolic wasting process driven by inflammatory cytokines. Comfort feeding, offering preferred foods in small portions as a pleasurable experience rather than a nutritional mandate, is the most appropriate approach for patients with disease-related cachexia. Appetite stimulants offer limited benefit in end-stage disease. Dexamethasone at 2 to 4 mg daily provides short-term appetite improvement lasting 2 to 4 weeks. Megestrol is not recommended in elderly patients due to risks of thromboembolism, adrenal suppression, and edema. Mirtazapine at 7.5 to 15 mg may be appropriate when depression and anorexia coexist, given its appetite-stimulating and sedating properties.
Artificial nutrition is generally inappropriate at the end of life. Percutaneous endoscopic gastrostomy tubes do not improve outcomes in patients with advanced dementia, a finding so well-established that both the American Geriatrics Society and the Choosing Wisely initiative explicitly recommend against their placement in this population. PEG tubes in advanced dementia do not prevent aspiration, do not prolong life, do not improve comfort, and may increase the risk of aspiration pneumonia and the use of physical restraints.
### Delirium at End of Life
Delirium is present in 50 to 88 percent of patients in the dying process, making it one of the most common and distressing complications of the terminal phase. The initial assessment should determine whether a reversible component exists, including medication effects, metabolic derangements, or infection, and whether addressing these factors is consistent with the patient's goals of care. Terminal or refractory delirium is part of the dying process and may not be fully reversible despite appropriate interventions.
Haloperidol at 0.5 to 2 mg every 4 to 6 hours is the first-line pharmacological intervention for delirium at end of life. For patients with dementia with Lewy bodies or Parkinson disease dementia, quetiapine at 12.5 to 25 mg is preferred to avoid the severe extrapyramidal reactions that typical antipsychotics can precipitate. When delirium is refractory and causes intractable suffering despite standard interventions, palliative sedation may be considered, typically using a midazolam infusion or phenobarbital. Family education is critically important during this phase, as caregivers need to understand that delirium is common in the dying process, that restless delirium does not necessarily indicate pain, and that the goal of treatment is comfort rather than restoration of consciousness.
A symptom management quick-reference chart for geriatric palliative care. Create a table format with columns: Symptom, First-Line Treatment, Dose in Elderly, Second-Line, and Key Pearls. Rows should include: (1) Pain — see pain lecture cross-reference, WHO ladder; (2) Dyspnea — morphine 2-5mg PO q4h, fan to face, O2 only if hypoxemic; (3) Nausea — haloperidol 0.5-2mg for chemical/metabolic, metoclopramide for gastroparesis, octreotide for obstruction; (4) Fatigue — methylphenidate 2.5-5mg BID, energy conservation; (5) Anorexia — comfort feeding, dexamethasone 2-4mg short-term, mirtazapine if depression; (6) Delirium — haloperidol 0.5-2mg q4-6h, address reversible causes, palliative sedation if refractory; (7) Secretions — glycopyrrolate 0.2mg SC q4h or scopolamine patch (positioned with calm, suctioning rarely helpful); (8) Anxiety — lorazepam 0.5mg SL q4-6h; (9) Constipation — senna + docusate, methylnaltrexone if opioid-induced. Include color-coded urgency indicators and cross-references to more detailed management guidelines.
## Prognostication
### General Principles
Accurate prognostication is essential for informed decision-making about goals of care, hospice referral, and the intensity of medical intervention, yet it remains one of the most challenging aspects of clinical medicine. Clinicians systematically overestimate prognosis, typically by a factor of 3 to 5 times the actual survival, as demonstrated by the seminal study by Christakis and Lamont in 2000. This optimistic bias delays hospice referral, prevents patients and families from having essential end-of-life conversations, and leads to care that is misaligned with realistic expectations. Prognostic uncertainty is inherent and irreducible, and clinicians should communicate prognosis in ranges rather than exact timeframes. The trajectory of functional decline is consistently identified as the most reliable prognostic indicator across disease types.
### Disease-Specific Prognostication
The trajectory of functional decline varies characteristically by disease category, and understanding these patterns is essential for anticipatory care planning. Cancer follows a relatively predictable trajectory characterized by a plateau of stable function followed by a steep decline over weeks to months at the end of life. Performance status measures such as the ECOG scale and the Palliative Performance Scale correlate well with survival in cancer; a PPS score of 50 percent or below corresponds to a median survival of approximately six months.
Heart failure follows an unpredictable trajectory punctuated by acute exacerbations and partial recoveries, often described as a "roller coaster" pattern. Each hospitalization tends to result in recovery to a lower functional baseline than the previous one, but the timing of the final decline is difficult to predict. The Seattle Heart Failure Model provides estimates of 1- to 5-year survival, and serial BNP trajectory combined with functional status assessment are the most useful clinical prognostic tools.
Chronic obstructive pulmonary disease follows a trajectory similar to heart failure, with recurrent exacerbations and partial recoveries. An FEV1 below 30 percent of predicted, oxygen dependence, recurrent exacerbations, and cor pulmonale suggest a poor prognosis, but the timing of death remains difficult to predict.
Dementia follows a slow, progressive decline that is the most challenging trajectory to prognosticate. The Functional Assessment Staging Test (FAST) stage 7C, characterized by loss of ambulation combined with inability to communicate meaningfully, corresponds to a median survival of approximately six months. The study by Mitchell and colleagues in 2009 demonstrated that nursing home residents with advanced dementia had a 6-month mortality rate of 25 percent, findings that inform hospice eligibility determinations.
Frailty as a clinical entity is best prognosticated using the Clinical Frailty Scale score and the trajectory of functional decline, which serve as the most useful general prognostic tools across disease categories.
### Surprise Question
The Surprise Question, "Would I be surprised if this patient died in the next 12 months?" is a simple screening tool that can be applied by any clinician to identify patients who may benefit from palliative care referral and goals-of-care discussions. When the answer is "no," the clinician should trigger a palliative care needs assessment and initiate a goals-of-care conversation. The Surprise Question has a sensitivity and specificity of approximately 70 percent each, making it an imperfect but practically useful screening tool that can be readily integrated into routine clinical workflow.
## Communication Skills
### SPIKES Protocol for Breaking Bad News
The SPIKES protocol provides a structured framework for delivering bad news that has been widely adopted in medical education and practice. The protocol begins with Setting, which involves ensuring a private, quiet environment where the clinician can sit down, allocate adequate time, and include important others as the patient wishes. Perception involves assessing the patient's current understanding by asking, "What is your understanding of your medical situation?" Invitation explores the patient's information preferences by asking, "How much information would you like me to share?" Knowledge sharing follows, delivering information clearly, avoiding medical jargon, and presenting information in small, digestible segments. Emotions are addressed by responding empathically to the patient's emotional response, with statements such as, "I can see this is difficult news." The final step, Strategy and Summary, outlines the plan for next steps and expresses the clinician's commitment to ongoing care.
### Goals-of-Care Conversations
The Serious Illness Conversation Guide, developed by Ariadne Labs, provides a comprehensive framework for goals-of-care discussions that extends beyond the delivery of bad news to explore the patient's values, fears, and treatment preferences. The guide proceeds through a series of carefully sequenced steps: setting up the conversation, assessing the patient's understanding and information preferences, sharing prognosis tailored to the patient's expressed desire for information, exploring what matters most to the patient if time is limited, exploring fears and worries, discussing functional goals with questions such as "What abilities are so important that you can't imagine living without them?", exploring treatment trade-offs with questions such as "How much are you willing to go through for the chance of more time?", making a clinical recommendation that is explicitly aligned with the patient's stated values, and documenting the conversation with plans for regular revisitation. This structured approach has been demonstrated to improve the quality of goals-of-care conversations and increase the concordance between patient wishes and the care they receive.
## Hospice Care
### Medicare Hospice Benefit
The Medicare Hospice Benefit provides comprehensive coverage for patients with a terminal illness and a life expectancy of six months or less if the disease runs its normal course, certified by two physicians. When a patient elects hospice, they can revoke the election at any time and return to standard Medicare coverage. The benefits covered under hospice include nursing visits, home health aide services, durable medical equipment, medications related to the terminal diagnosis, social work, chaplaincy, volunteer services, bereavement support for the family extending 13 months after the patient's death, respite care (up to 5 days to provide caregiver relief), and continuous care during crisis episodes. Benefits not covered include curative treatments directed at the terminal diagnosis and most hospitalizations unless specifically arranged by the hospice team for symptom management. Hospice care can be delivered in multiple settings, including the patient's home (the most common setting), nursing homes, dedicated inpatient hospice facilities, and hospitals.
### Hospice Eligibility Guidelines (LCD)
Local coverage determinations for hospice eligibility incorporate general criteria including a Palliative Performance Scale score of 70 percent or below, declining functional status, unintentional weight loss, recurrent infections, and frequent hospitalizations. Disease-specific criteria have been developed for heart failure, COPD, dementia, cancer, renal failure, liver disease, stroke, and amyotrophic lateral sclerosis, providing clinicians with structured frameworks for certifying hospice eligibility across the range of life-limiting diagnoses.
### Barriers to Hospice
Multiple barriers contribute to the persistent underutilization and late referral to hospice care. Late referral, with a median enrollment of only 18 days and 25 percent of patients dying within 3 days of enrollment, deprives patients and families of the full spectrum of hospice benefits. Prognostic uncertainty is particularly challenging in non-cancer diagnoses, where the unpredictable disease trajectory makes the six-month prognosis requirement difficult to meet with confidence. Patient and family reluctance to "give up hope" is a powerful psychological barrier, as is the cultural and religious context in which some communities approach death and dying. Physician reluctance to prognosticate and initiate end-of-life discussions perpetuates late referral. The pervasive misconception that hospice equates to "giving up" must be actively countered by reframing hospice as intensive comfort care focused on maximizing quality of life during a critical period.
A comparison timeline showing illness trajectories and palliative care integration for four disease types common in elderly patients. Display four horizontal timelines side by side. (1) Cancer: show a plateau of function followed by a steep decline over weeks-months at end of life — mark "palliative care" beginning at diagnosis extending through hospice at the steep decline. (2) Heart Failure/COPD: show a gradual decline punctuated by acute exacerbations (dips) with partial recoveries, each recovery reaching a lower baseline — mark "palliative care" starting after first hospitalization. (3) Dementia/Frailty: show a slow, steady, progressive decline over years — mark "palliative care" starting at moderate-stage diagnosis. (4) Sudden Death (stroke, MI): show a flat line followed by sudden drop — mark "advance care planning" as the only intervention window. For each trajectory, show where hospice enrollment typically occurs vs. where it SHOULD ideally occur (earlier). Include the "Surprise Question" at the point where it would trigger palliative needs assessment. Label the x-axis as "Time" and y-axis as "Function/Health Status."
## Key Clinical Pearls
- Palliative care is appropriate at ANY stage of serious illness — not just at end of life; early palliative care improves quality of life and may extend survival (Temel trial)
- Opioids are the first-line pharmacotherapy for dyspnea at end of life — low-dose morphine (2-5 mg PO) is safe, effective, and does not hasten death at appropriate doses
- Clinicians overestimate prognosis by 3-5x — when communicating prognosis, provide a range and be prepared to be wrong
- The Surprise Question ("Would I be surprised if this patient died within 12 months?") is a useful trigger for initiating goals-of-care conversations and palliative care referral
- Hospice enrollment at 18 days median is far too late — patients and families benefit most from hospice when enrolled ≥3 months before death
- PEG tubes do not improve outcomes in advanced dementia — the AGS and Choosing Wisely explicitly recommend against them
- "Hope" and palliative care are not mutually exclusive — reframe palliative care as "intensive comfort care" or "adding quality to life" rather than "giving up"
## References
1. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med*. 2010;363(8):733-742.
2. National Consensus Project for Quality Palliative Care. *Clinical Practice Guidelines for Quality Palliative Care*. 4th ed. 2018.
3. Bernacki RE, Block SD. Communication about serious illness care goals: a review and synthesis of best practices. *JAMA Intern Med*. 2014;174(12):1994-2003.
4. Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. *N Engl J Med*. 2009;361(16):1529-1538.
5. Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. *BMJ*. 2000;320(7233):469-472.